Peritoneal-plasma barrier
- PMID: 8849943
- DOI: 10.1007/978-1-4613-1247-5_4
Peritoneal-plasma barrier
Abstract
The peritoneal-plasma barrier is a pharmacologic entity of importance for treatment planning in patients with malignant tumours confined to the abdominal cavity. This physiologic barrier limits the resorption of drugs from the peritoneal cavity into the blood. The sequestration of chemotherapeutic agents improves their locoregional cytotoxicity and reduces their systemic toxicity. The physical nature of the peritoneal-plasma barrier has not been clearly defined. Further pharmacologic studies need to be performed in order to achieve a better understanding of this interesting metabolic phenomenom. At present, it is suspected that a diffusion barrier exists that consists of subserosal tissues or blood vessel walls. As postulated by Maher [29], the capillary wall appears to offer the dominant resistance to the transfer of larges solutes. The mesothelium and intersitium impede their movement to a lesser extent, and their removal during cytoreductive surgery does not affect the pharmacology of postoperative intraperitoneal chemotherapy.
Similar articles
-
Pharmacokinetics of the peritoneal-plasma barrier after systemic mitomycin C administration.Cancer Treat Res. 1996;82:41-52. doi: 10.1007/978-1-4613-1247-5_3. Cancer Treat Res. 1996. PMID: 8849942
-
Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer.Cancer Treat Rep. 1978 Jan;62(1):1-11. Cancer Treat Rep. 1978. PMID: 626987
-
The use of intraperitoneal chemotherapy.Important Adv Oncol. 1985:218-25. Important Adv Oncol. 1985. PMID: 3916741 Review.
-
Pharmacokinetics and tissue distribution of intraperitoneal paclitaxel with different carrier solutions.Cancer Chemother Pharmacol. 2003 Nov;52(5):405-10. doi: 10.1007/s00280-003-0680-2. Epub 2003 Jul 23. Cancer Chemother Pharmacol. 2003. PMID: 12879282
-
The transport barrier in intraperitoneal therapy.Am J Physiol Renal Physiol. 2005 Mar;288(3):F433-42. doi: 10.1152/ajprenal.00313.2004. Am J Physiol Renal Physiol. 2005. PMID: 15692055 Review.
Cited by
-
Effect of Liposomal Doxorubicin in Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC).J Cancer. 2018 Oct 20;9(23):4301-4305. doi: 10.7150/jca.26860. eCollection 2018. J Cancer. 2018. PMID: 30519333 Free PMC article.
-
Stimulated upregulation of HO-1 is associated with inadequate response of gastric and ovarian cancer cell lines to hyperthermia and cisplatin treatment.Oncol Lett. 2019 Aug;18(2):1961-1968. doi: 10.3892/ol.2019.10489. Epub 2019 Jun 18. Oncol Lett. 2019. PMID: 31423266 Free PMC article.
-
Intraperitoneal Paclitaxel is useful as adjuvant chemotherapy for advanced gastric cancer with serosal exposure.Case Rep Oncol. 2014 Jan 24;7(1):58-64. doi: 10.1159/000358379. eCollection 2014 Jan. Case Rep Oncol. 2014. PMID: 24575018 Free PMC article.
-
Effect of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on relapse pattern in primary epithelial ovarian cancer: a propensity score based case-control study.J Gynecol Oncol. 2018 May;29(3):e53. doi: 10.3802/jgo.2018.29.e53. Epub 2018 Mar 12. J Gynecol Oncol. 2018. PMID: 29533028 Free PMC article.
-
Exosomal miR-493 suppresses MAD2L1 and induces chemoresistance to intraperitoneal paclitaxel therapy in gastric cancer patients with peritoneal metastasis.Sci Rep. 2024 May 2;14(1):10075. doi: 10.1038/s41598-024-60967-x. Sci Rep. 2024. PMID: 38698201 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Research Materials